Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05557591
Title Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 >= 50%
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA | ESP | DEU

Additional content available in CKB BOOST